Skip to main content
. Author manuscript; available in PMC: 2016 May 1.
Published in final edited form as: J Am Coll Surg. 2015 Feb 16;220(5):863–871.e2. doi: 10.1016/j.jamcollsurg.2015.01.058

Table 3.

Final pathologic staging for all patients in the cohort.

Final Pathological
Stage		 Entire
Cohort (%)		 Received Neoadjuvant
Chemotherapy
(N = 103, 43%)		 No neoadjuvant
chemotherapy
(N = 135, 57%)
T Stage
  T0 10 (4.2%) 9 (8.7%)* 1 (0.7%)**
  T1 63 (26%) 7 (6.8%) 56 (41%)
  T2 26 (11%) 13 (13%) 13 (10%)
  T3 68 (29%) 43 (42%) 25 (19%)
  T4 71 (30%) 31 (30%) 40 (30%)
N Stage
  N0 116 (49%) 46 (45%) 70 (52%)
  N1 49 (21%) 24 (23%) 25 (19%)
  N2 28 (12%) 13 (13%) 15 (11%)
  N3 45 (19%) 20 (19%) 25 (19%)
M Stage
  M0 237 (100%) 102 (99%) 135 (100%)
  M1 1 (0.4%) 1 (1.0%)*** 0 (0%)
*

All patients received neoadjuvant chemotherapy and had a complete pathological response

**

Patient had signet cell adenocarcinoma on specimen from pre-operative endoscopic biopsy, but no identifiable adenocarcinoma on final pathology, including at the biopsy site.

***

One patient had a previously undetected omental implant detected in the surgical specimen after curative intent total gastrectomy.